301 related articles for article (PubMed ID: 25377157)
1. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
2. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
[TBL] [Abstract][Full Text] [Related]
3. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948
[TBL] [Abstract][Full Text] [Related]
4. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
5. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
Sharma S; Beck J; Mita M; Paul S; Woo MM; Squier M; Gadbaw B; Prince HM
Invest New Drugs; 2013 Aug; 31(4):974-85. PubMed ID: 23377661
[TBL] [Abstract][Full Text] [Related]
6. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
Shapiro GI; Frank R; Dandamudi UB; Hengelage T; Zhao L; Gazi L; Porro MG; Woo MM; Lewis LD
Cancer Chemother Pharmacol; 2012 Feb; 69(2):555-62. PubMed ID: 22057852
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
[No Abstract] [Full Text] [Related]
10. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
Hamberg P; Woo MM; Chen LC; Verweij J; Porro MG; Zhao L; Li W; van der Biessen D; Sharma S; Hengelage T; de Jonge M
Cancer Chemother Pharmacol; 2011 Sep; 68(3):805-13. PubMed ID: 21706316
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.
Savelieva M; Woo MM; Schran H; Mu S; Nedelman J; Capdeville R
Eur J Clin Pharmacol; 2015 Jun; 71(6):663-672. PubMed ID: 25939707
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
Morita S; Oizumi S; Minami H; Kitagawa K; Komatsu Y; Fujiwara Y; Inada M; Yuki S; Kiyota N; Mitsuma A; Sawaki M; Tanii H; Kimura J; Ando Y
Invest New Drugs; 2012 Oct; 30(5):1950-7. PubMed ID: 21964801
[TBL] [Abstract][Full Text] [Related]
13. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
14. Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate.
Moore K; Zannikos P; Solanki B; Greenspan A; Verhaeghe T; Brashear HR
J Clin Pharmacol; 2012 May; 52(5):738-46. PubMed ID: 21566203
[TBL] [Abstract][Full Text] [Related]
15. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.
Bailey H; McPherson JP; Bailey EB; Werner TL; Gupta S; Batten J; Reddy G; Bhat G; Sharma S; Agarwal N
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1059-1071. PubMed ID: 27744565
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Rathkopf D; Wong BY; Ross RW; Anand A; Tanaka E; Woo MM; Hu J; Dzik-Jurasz A; Yang W; Scher HI
Cancer Chemother Pharmacol; 2010 May; 66(1):181-9. PubMed ID: 20217089
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
[TBL] [Abstract][Full Text] [Related]
19. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.
Srinivas NR
Xenobiotica; 2017 Apr; 47(4):354-368. PubMed ID: 27226420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
